Creatinine normalization approach to diluted urine samples screened by LC-MS/MS method

Objectives: Urine is the most used matrix in drug analysis; however, it is susceptible to adulteration or tampering. Urine creatinine is the most important urine integrity parameter used as an indicator of dilution. This study aimed to evaluate the prevalence of diluted urine samples and the change...

Full description

Saved in:
Bibliographic Details
Published inInternational Journal of Medical Biochemistry Vol. 7; no. 2; pp. 95 - 100
Main Authors Karakukcu, Cigdem, Kocer, Derya, Uzen, Veysel, Saracoglu, Hatice
Format Journal Article
LanguageEnglish
Published Istanbul KARE Publishing 2024
Kare Publishing
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives: Urine is the most used matrix in drug analysis; however, it is susceptible to adulteration or tampering. Urine creatinine is the most important urine integrity parameter used as an indicator of dilution. This study aimed to evaluate the prevalence of diluted urine samples and the change in positivity after creatinine normalization. Methods: Urine samples screened by the LC-MS/MS method over a 3.5-year period (n=21,927) were included in the study. Positivity rates were evaluated in both total and diluted urine samples. Additionally, the impact of creatinine normalization on samples with substance concentrations above the limit of quantitation (LOQ) and below the cut-off was investigated. Results: A total of 350,832 tests were conducted on 21,927 urine samples, resulting in an overall positivity rate of 21.2% (n=4652). The ratio of diluted urine was 1.6% (n=343), with 61.5% (n=211) testing negative (<LOQ), 23.3% (n=80) testing positive (at least one substance >cut-off), and 15.2% (n=52) testing above LOQ and below cut-off. After creatinine normalization in diluted urines, the sample positivity rate increased from 23.3% (n=80) to 33.8% (n=116) (p <0.001), and the substance positivity rate increased from 2.3% (n=125) to 3.9% (n=212) (p <0.001). Conclusion: Precautions should be taken in reporting diluted urine samples to avoid reporting false negative results. The creatinine normalization approach shows promise in laboratories using quantitative screening methods such as LC-MS/MS for samples with substance concentrations above the LOQ and below the cut-off. However, more clinical and laboratory collaboration is needed for its routine application. Keywords: Creatinine normalization, diluted urine, illicit drug, screening test
AbstractList Objectives: Urine is the most used matrix in drug analysis; however, it is susceptible to adulteration or tampering. Urine creatinine is the most important urine integrity parameter used as an indicator of dilution. This study aimed to evaluate the prevalence of diluted urine samples and the change in positivity after creatinine normalization. Methods: Urine samples screened by the LC-MS/MS method over a 3.5-year period (n=21,927) were included in the study. Positivity rates were evaluated in both total and diluted urine samples. Additionally, the impact of creatinine normalization on samples with substance concentrations above the limit of quantitation (LOQ) and below the cut-off was investigated. Results: A total of 350,832 tests were conducted on 21,927 urine samples, resulting in an overall positivity rate of 21.2% (n=4652). The ratio of diluted urine was 1.6% (n=343), with 61.5% (n=211) testing negative (<LOQ), 23.3% (n=80) testing positive (at least one substance >cut-off), and 15.2% (n=52) testing above LOQ and below cut-off. After creatinine normalization in diluted urines, the sample positivity rate increased from 23.3% (n=80) to 33.8% (n=116) (p <0.001), and the substance positivity rate increased from 2.3% (n=125) to 3.9% (n=212) (p <0.001). Conclusion: Precautions should be taken in reporting diluted urine samples to avoid reporting false negative results. The creatinine normalization approach shows promise in laboratories using quantitative screening methods such as LC-MS/MS for samples with substance concentrations above the LOQ and below the cut-off. However, more clinical and laboratory collaboration is needed for its routine application. Keywords: Creatinine normalization, diluted urine, illicit drug, screening test
[LANGUAGE= "English"] INTRODUCTION: Urine is the most used matrix in drug analysis; however, it is susceptible to adulteration or tampering. Urine creatinine is the most important urine integrity parameter used as an indicator of dilution. This study aimed to evaluate the prevalence of diluted urine samples and the change in positivity after creatinine normalization.METHODS: Urine samples screened by the LC-MS/MS method over a 3.5-year period (n=21,927) were included in the study. Positivity rates were evaluated in both total and diluted urine samples. Additionally, the impact of creatinine normalization on samples with substance concentrations above the limit of quantitation (LOQ) and below the cut-off was investigated.RESULTS: A total of 350,832 tests were conducted on 21,927 urine samples, resulting in an overall positivity rate of 21.2% (n=4652). The ratio of diluted urine was 1.6% (n=343), with 61.5% (n=211) testing negative (<LOQ), 23.3% (n=80) testing positive (at least one substance >cut-off), and 15.2% (n=52) testing above LOQ and below cut-off. After creatinine normalization in diluted urines, the sample positivity rate increased from 23.3% (n=80) to 33.8% (n=116) (p<0.001), and the substance positivity rate increased from 2.3% (n=125) to 3.9% (n=212) (p<0.001).DISCUSSION AND CONCLUSION: Precautions should be taken in reporting diluted urine samples to avoid reporting false negative results. The creatinine normalization approach shows promise in laboratories using quantitative screening methods such as LC-MS/MS for samples with substance concentrations above the LOQ and below the cut-off. However, more clinical and laboratory collaboration is needed for its routine application.
Author Uzen, Veysel
Karakukcu, Cigdem
Kocer, Derya
Saracoglu, Hatice
Author_xml – sequence: 1
  fullname: Karakukcu, Cigdem
– sequence: 2
  fullname: Kocer, Derya
– sequence: 3
  fullname: Uzen, Veysel
– sequence: 4
  fullname: Saracoglu, Hatice
BookMark eNptUc9PwyAUJmYmzrm7xyaeuwGlLRyXxl_JFg9T441QoI6lhQrtQf962WZiTHwcHu_L9z1477sEE-usBuAawQUiJSFLs-_qBYaYLPJYojMwxQWiaUHw2yTec1qmOCvwBZiHYGpIoghhRKbgtfJaDMYaqxPrfCda8xVrZxPR994JuUsGlyjTjoNWyegPvCC6vtUhCdJrbSNcfybrKt1sl5tt0ulh59QVOG9EG_T8J8_Ay93tc_WQrp_uH6vVOpWYUJRqJhjNGCJ5ARtJFVEZEgQVJSKKUVVGiBJY1BQhVsMyBpaM0EIx0WRKsWwGbk59418_Rh0Gvnejt_FJnkGWZ8c5f1nvotXc2MYNXsjOBMlXJcthXjBWRtbiH1Y8SndGxoU3JuJ_BPAkkN6F4HXDe2864T85gvzoCz_4wg--8KMv2TcLTYAv
ContentType Journal Article
Copyright COPYRIGHT 2024 KARE Publishing
2024. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: COPYRIGHT 2024 KARE Publishing
– notice: 2024. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
DOI 10.14744/ijmb.2024.57441
DatabaseName CrossRef
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: 7X7
  name: ProQuest Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 2618-642X
EndPage 100
ExternalDocumentID A795056997
10_14744_ijmb_2024_57441
GroupedDBID AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
M~E
3V.
7X7
7XB
8FI
8FJ
8FK
AAFWJ
ABDBF
ABUWG
AFKRA
AFPKN
ALIPV
AZQEC
BENPR
CCPQU
DWQXO
EN8
FYUFA
GROUPED_DOAJ
HMCUK
IAO
IHR
INH
ITC
K9.
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
UKHRP
ID FETCH-LOGICAL-c2481-e9a983914560fc8d4d31a416714d98d7c8d8406b8119b077772c9486d9af3dd93
IEDL.DBID 7X7
ISSN 2587-2362
IngestDate Thu Sep 19 06:21:26 EDT 2024
Wed May 29 17:42:02 EDT 2024
Tue May 28 06:11:27 EDT 2024
Fri Aug 23 01:48:38 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2481-e9a983914560fc8d4d31a416714d98d7c8d8406b8119b077772c9486d9af3dd93
OpenAccessLink https://www.proquest.com/docview/3095347412/abstract/?pq-origsite=%requestingapplication%
PQID 3095347412
PQPubID 5083811
PageCount 6
ParticipantIDs proquest_journals_3095347412
gale_infotracmisc_A795056997
gale_infotracacademiconefile_A795056997
crossref_primary_10_14744_ijmb_2024_57441
PublicationCentury 2000
PublicationDate 2024-00-00
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – year: 2024
  text: 2024-00-00
PublicationDecade 2020
PublicationPlace Istanbul
PublicationPlace_xml – name: Istanbul
PublicationTitle International Journal of Medical Biochemistry
PublicationYear 2024
Publisher KARE Publishing
Kare Publishing
Publisher_xml – name: KARE Publishing
– name: Kare Publishing
SSID ssib044741214
ssj0002513684
Score 2.2880821
Snippet Objectives: Urine is the most used matrix in drug analysis; however, it is susceptible to adulteration or tampering. Urine creatinine is the most important...
[LANGUAGE= "English"] INTRODUCTION: Urine is the most used matrix in drug analysis; however, it is susceptible to adulteration or tampering. Urine creatinine...
SourceID proquest
gale
crossref
SourceType Aggregation Database
StartPage 95
SubjectTerms Analysis
Collaboration
Creatinine
Laboratories
Medical screening
Methods
Urine
Title Creatinine normalization approach to diluted urine samples screened by LC-MS/MS method
URI https://www.proquest.com/docview/3095347412/abstract/
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LaxsxEBZOcsklNLQlzsPoUCg9bDZ6eLU6lcTYmFKb0sTFNyHtaMEhWSe1c8ilvz0z690EQ-geBCvti9Fo5pvRzgxjX0plswhlnoDwCg2Uskhybzw2Oooc9VMAih2eTLPxTP-Y9-cdNm5jYei3ylYm1oIalgX5yFNFidE06j-Z-kBegGKdfn94TKh-FO2zNsU0dtiekAgrkLPN_FWx6vrGZr-QZDRqdZXV5YhlH1eZRDHe7GHilTpd3N4HtB2lPu_jqdjSWe9L7lodjT6wgwZH8svNxB-yTqw-sj-DGgJWiBx5RWD0romy5G3qcL5eclggt0Xg5GePfOUpP_CKo_hAkxa7wzP_OUgm1-nkmm_qS39is9HwZjBOmsIJSSF1LpJovUXgIxAcIfFz0KCER-RlhAabg8EutOuykAthw4XBQxZW5xlYXyoAqz6z3WpZxSPGrekXQoEqg4261JReEFCrgwkSgpSmy761pHEPm_wYjuwKIqMjMjoio6vJ2GVfiXaOlg5NoG8iAPBNlITKXRpLeMxafOrp1pXI8sX2cEt91yy5lXtjkOP_D5-wffqmjR_llO2u_z7FM0QW69CrmabH9q6G01-_e7V9ju3k3_AFIZXMgg
link.rule.ids 315,786,790,870,4043,12083,21416,27956,27957,27958,31754,33779,43345,43840
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swELdG9wAviGkgGB_zw6SJh6z4o3H8NFUVVWEtL7RT3yw750hFW9rR8sB_v7vUBVVC5CFSHCuJfjnf_e5s3zH2rVI2j1AVGQiv0EGpyqzwxuNJR1GgfQpAe4dHd_lgom-nnWkKuC3TssqNTmwUNcxLipG3FSVG02j_5M_Fv4yqRtHsaiqhscM-aqU0Lekz0xdzqpvuaZaQNDPacpU3RYhlB8eWROWdZi6xp27PHv4G9Bil_tHBS7Flqd7W140R6h-w_cQeeXf9uz-xD7H-zH73GuJXI1_kNVHQP2lvJd8kDOerOYcZylgETtH1yJeesgIvOSoNdGSxOTzzYS8b3bdH93xdVfqQTfrX494gS-USslLqQmTReot0RyAlQsgL0KCER75lhAZbgMEm9ObyUAhhw5XBQ5ZWFzlYXykAq45Yq57X8ZhxazqlUKCqYKOuNCUVBLTlYIKEIKU5YZcbaNxinRXDkTdBMDqC0RGMroHxhH0n7BwNmNWjL31a949votRTrmsssTBr8alnWz1R0Mvt2xv0XRpoS_cqFl_ev_2V7Q7Go6Eb3tz9OmV79H3rSMoZa60en-I5cotVuGgE6D_RLsf1
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Creatinine+normalization+approach+to+diluted+urine+samples+screened+by+LC-MS%2FMS+method&rft.jtitle=International+Journal+of+Medical+Biochemistry&rft.au=Karakukcu%2C+Cigdem&rft.au=Kocer%2C+Derya&rft.au=Uzen%2C+Veysel&rft.au=Saracoglu%2C+Hatice&rft.date=2024&rft.pub=KARE+Publishing&rft.issn=2587-2362&rft.volume=7&rft.issue=2&rft.spage=95&rft_id=info:doi/10.14744%2Fijmb.2024.57441&rft.externalDocID=A795056997
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2587-2362&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2587-2362&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2587-2362&client=summon